Understanding Section 340B Program for Covered Entities

Section 340B can protect your hospital's margin or quietly cost you hundreds of thousands of dollars a year. The difference comes down to how well your team tracks eligibility, pricing, and orphan drug rules. 340B Orphan Drug Solutions helps covered entities capture every dollar they are owed under the Section 340B program, without missing a compliance requirement along the way.

If your pharmacy team is buried in manufacturer rule changes and quarterly orphan drug updates, you are not alone. Keep reading to see how the 340B healthcare law works, who qualifies, and how a focused compliance partner can free up dozens of hours a quarter while protecting your savings.

What is Section 340B: Key Highlights

Section 340B is a law covered under the Public Health Service Act. It is officially titled as ‘Limitation on Prices of Drugs Purchased by Covered Entities’. It is codified at 42 U.S.C. 256b under the Act. This law was enacted through Section 602 of the Veterans Health Care Act of 1992, Public Law 102-585.

The US Congress built it around a simple trade, which was: manufacturers get access to Medicaid and Medicare Part B, and in exchange they agree to sell outpatient drugs to safety net providers at a capped price.

The statute does not hand out discounts directly. Instead, it instructs the Health and Human Services (HHS) Secretary to enter into a pharmaceutical pricing agreement (PPA) with each drug manufacturer that wants its outpatient drugs covered under Medicaid and Medicare Part B.

By signing that agreement, a manufacturer commits to charging registered covered entities no more than the 340B ceiling price for covered outpatient drugs. Congress built the law this way so participation in Medicaid becomes the lever that pulls manufacturers into the 340B program.

What is the 340B Ceiling Price?

The ceiling price is calculated by the Health Resources and Services Administration (HRSA) every quarter. The calculation is based on pricing that data manufacturers report to Centers for Medicare & Medicaid Services (CMS). That is why the discount a hospital sees on a given drug can shift from one quarter to the next.

340B Ceiling Price Formula

AMP − URA = 340B Ceiling Price

AMP = Average Manufacturer Price (based on the smallest billable unit of the drug)

URA = Unit Rebate Amount (minimum 23.1% for most brand-name drugs, minimum 13% for generic and over-the-counter drugs)

Lawmakers were explicit about why they wrote the statute this way. The original House report describes the goal as allowing covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. HRSA's Office of Pharmacy Affairs, operating under delegated authority from the HHS Secretary, administers the program day to day, from covered entity registration through ceiling price enforcement.

Costs Associated with 340B Sales

As per the Congressional Research Service’s Overview of the 340B Drug Discount Program:

• 340B purchases account for roughly 7.2 percent of the entire United States drug market

• In 2021, total program sales reached close to 44 billion dollars.

• A ceiling price violation or diversion finding puts access to a multi-billion dollar program at risk, not just a small administrative fine.

Orphan Drugs

Under Section 340B(e), drugs designated for a rare disease or condition are excluded from mandatory 340B pricing for certain hospital types, unless the manufacturer voluntarily agrees to offer a discount.

That single exception is where most hospitals lose money they never knew they were entitled to capture.

Prime Vendor Program

The 340B healthcare law also created a Prime Vendor Program. The Prime Vendor Program has been run by Apexus since 2004. Owing to this, covered entities can negotiate sub-ceiling prices as a group rather than facing manufacturers alone.

Every hospital in the US is not obligated to join the Prime Vendor Program. However, most hospitals use it because it gives smaller facilities the same negotiating leverage as much larger health systems.

Why the Section 340B Program Matters for Hospitals Like Yours

Every dollar saved through the Section 340B program is a dollar your hospital can put back into direct patient care. For safety net providers operating on thin margins, that difference shows up fast, especially:

• In staffing levels

• In service lines that stay open

• In how many uninsured patients you can afford to treat.

This difference is starkly visible for orphan drugs. This is because:

• Rare disease therapies are often the most expensive line items on a specialty pharmacy budget.

• Their 340B status depends on manufacturer discretion rather than statute; the rules shift every quarter.

Thus, a hospital that is not actively tracking those changes is very likely leaving discretionary savings unclaimed. This can happen quarter after quarter, without ever knowing it.

340B Covered Entity Eligibility

Section 340B(a)(4) of the Public Health Service Act names the specific 340B covered entities that qualify, and each category falls into one of two groups, which are:

1. Hospital-based entities

2. Non-hospital entities

Each healthcare entity has its own eligibility path. As per 340B Drug Pricing Program Eligibility, eligibility is not a one-time event. Covered entities must recertify every year. Also, they must notify HRSA's Office of Pharmacy Affairs the moment their status changes. If a facility loses eligibility, it has to stop purchasing 340B-priced drugs right away.

Eligibility for Hospital-Based Covered Entities

Here are the eligibility criteria for hospital-based entities: